MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
Objectives Real-world studies have shown that Mayo Additive Staging System (MASS) −3 and MASS-4 are suitable for prognostic stratification in Chinese patients with newly diagnosed multiple myeloma (NDMM), but there is no clear evidence of their utility in transplant-eligible NDMM patients. We aimed...
Saved in:
Main Authors: | Fan Yang, Junru Liu, Jingli Gu, Meilan Chen, Beihui Huang, Lifen Kuang, Juan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Annals of Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2519671 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01) -
Autologous stem cell transplantation in newly diagnosed multiple myeloma patients with severe renal failure requiring hemodialysis. A single-center experience
by: Yu. I. Kliuchagina, et al.
Published: (2024-09-01) -
Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma
by: S. V. Semochkin, et al.
Published: (2023-12-01) -
The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01) -
Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients
by: M. V. Solovev, et al.
Published: (2019-01-01)